Bortezomib-induced acute neutrophilic dermatosis

• Published in: Annales de dermatologie et de vénéréologie Vol. 136; no. 5; p. 443
• Main Authors: Tanguy-Schmidt, A, Avenel-Audran, M, Croué, A, Lissandre, S, Dib, M, Zidane-Marinnes, M, Moles, M-P, Hunault-Berger, M
• Format: Journal Article
• Language: French
• Published: France 01.05.2009
• Subjects: Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Apoptosis - drug effects; Boronic Acids - adverse effects; Boronic Acids - therapeutic use; Bortezomib; Humans; Male; Multiple Myeloma - drug therapy; Neutrophils - drug effects; Neutrophils - pathology; Pyrazines - adverse effects; Pyrazines - therapeutic use; Skin Diseases - chemically induced; Skin Diseases - pathology; Sweet Syndrome - chemically induced; Sweet Syndrome - pathology
• ISSN: 0151-9638
• DOI: 10.1016/j.annder.2008.11.021

Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present. The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.